This is a significant clinical milestone for Fractyl, de-risking the Rejuva platform and expanding the pipeline. Monitor for first patient dosing and preliminary data in H2 2026, which could be a major catalyst. The stock may re-rate as the company transitions to a dual clinical-stage entity.
Price Chart
Executive Summary
Fractyl Health received Clinical Trial Authorization in the Netherlands to begin a Phase 1/2 first-in-human study of RJVA-001, an AAV-based gene therapy for type 2 diabetes. This advances the company to a dual clinical-stage pipeline alongside its Revita platform, with first dosing and preliminary data expected in H2 2026, funded within existing cash runway.
Key Facts
- Received Clinical Trial Authorization in the Netherlands for RJVA-001 Phase 1/2 first-in-human study in type 2 diabetes.
- RJVA-001 is the first AAV-based gene therapy candidate to enter clinical development for T2D.
- First patient dosing and preliminary data expected in H2 2026, subject to site activation.
- Rejuva clinical development funded within existing cash runway into early 2027, beyond REMAIN-1 pivotal readout; no change to capital plans.
- Study is open-label, multicenter, single-ascending-dose, with 3+3+3 dose cohorts and optional expansion of up to 20 participants.
- Fractyl also plans to conduct the study at sites in Australia, with regulatory feedback expected in Q3 2026.
Financial Impact
No financial figures disclosed; clinical development funded within existing cash runway.
Risk Factors
- Clinical trial failure or safety issues in first-in-human study.
- Regulatory delays in Australia or other jurisdictions.
- Dilution risk if additional capital is needed beyond current runway.
- Competition from existing GLP-1 therapies and other gene therapy candidates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291742 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $1.13 | awaiting T+5 | — | $1.08 (−4.42%) |
Oct 16, 2026 10d ago | 8-K | $1.55 $1.08 | ▼ −30.32% | ▼ −30.42% | $1.08 (−30.32%) |
Oct 13, 2026 12d ago | SC 13G | $4.03 $1.33 | ▼ −66.96% | ▼ −65.80% | $1.08 (−73.17%) |
Aug 10, 2026 10w ago | 8-K | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Aug 10, 2026 10w ago | Press Release | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Jul 15, 2026 14w ago | 8-K | $0.9100 $0.7580 | ▼ −16.70% | ▼ −15.72% | $1.08 (+18.68%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Insider Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.99% | $1.08 (+49.19%) |
Jun 4, 2026 20w ago | 8-K | $0.7340 $0.7240 | ▼ −1.36% | ▲ +1.19% | $1.08 (+47.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers